Home Daily Intelligence Tracker
    • Plans Blog Contact
    BioCryst Pharmaceuticals Inc logo
    BCRX

    BioCryst Pharmaceuticals Inc

    MaveScore 40 Low model confidence
    Last Price US$10.45 As of Jul 10, 2026
    DCF Fair Price US$19.32 Research estimate · Jul 10, 2026 +80.3% vs price
    Market Cap US$2.7b Company size context
    7D Performance 6.20% Past 7 days
    1Y Performance 17.61% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 40 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    13/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    12/25 Mixed

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    5/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    10/15 Mixed

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Favors positive earnings, positive cash flow, and lower multiples.
    • Rewards less dilutive share behavior and enough size for liquid research coverage.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    BioCryst Pharmaceuticals Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLAD Read More

    BioCryst Pharmaceuticals Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    BioCryst Pharmaceuticals Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 06, 2026

    Quarterly result summary

    Revenue was $148.3M (reported). Operating income was $54.2M. Cash was $260.8M.

    Revenue $148.3M reported
    Operating income $54.2M reported
    Cash $260.8M reported

    What changed

    • Revenue reported to $148.3M.

    Guidance / outlook

    we expect investors and financial analysts to compare our results.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 06, 2026 SEC filing FORM 8-K May 06, 2026 SEC filing 10-K Feb 26, 2026 SEC filing FORM 8-K Feb 26, 2026 Earnings release PRESS RELEASE Feb 26, 2026 SEC filing FORM 8-K Jan 12, 2026 Earnings release PRESS RELEASE Jan 12, 2026 SEC filing 10-Q Nov 04, 2025 SEC filing FORM 8-K Nov 03, 2025 Earnings release PRESS RELEASE Nov 03, 2025 SEC filing EXHIBIT 99.2 Oct 14, 2025

    Recent News



    There is no doubt that Biocryst Pharmaceuticals Inc. (BCRX) ticks all the boxes. – Sete News
    16 minutes ago
    BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by BNP Paribas Financial Markets
    17 hours ago
    What technical indicators reveal about BCRX stock – US Post News
    2 days ago

    Earnings Per Share

    Score 4.00/5
    BioCryst Pharmaceuticals Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 2.68/5
    BioCryst Pharmaceuticals Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    BioCryst Pha... BCRX US$2.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.53/5
    BioCryst Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    BioCryst Pha... BCRX US$2.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 1.72/5
    BioCryst Pharmaceuticals Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    BioCryst Pha... BCRX US$2.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    BioCryst Pharmaceuticals Inc logo

    BioCryst Pharmaceuticals Inc

    US$10.45

    US$19.32

    +80.3% vs price

    US$2.7b

    6.20%

    17.61%